Sterling Bay has recently secured four new biotech tenants at 2430 N. Halsted, a state-of-the-art scientific research facility in Chicago’s Lincoln Park. These new tenants include Seq Biomarque, CeGaT Corporation, EVOQ Therapeutics and Cyclopure.
Seq Biomarque is a leading research and diagnostic technologies firm that specializes in developing highly sensitive blood-based multi-factor screening and diagnostic tests for Alzheimer’s disease. Meanwhile, CeGaT Corporation is making its debut in the U.S., focusing on advancements in genomics and personalized medicine.
EVOQ Therapeutics was spun out of the University of Michigan’s on-campus lab with the goal of revolutionizing autoimmune disease treatment through novel immunotherapies. And finally, Cyclopure specializes in water purification and treatment technologies and will be relocating to this hub from the Illinois Science + Technology Park.
The transactions were negotiated by Dave Gloor and Daniella Hemsley on behalf of Sterling Bay while Jonathan Metzl and Jack Deroche represented Cyclopure through Cushman & Wakefield. This life sciences hub offers adaptable lab spaces for biotech firms at various stages of growth with flexible options to support startups as they scale their operations.
According to Andy Gloor, CEO of Sterling Bay: “Our focus is creating a range
